Determination of urinary alpha-aminoadipic semialdehyde by LC-MS/MS in patients with congenital metabolic diseases

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1:944:141-3. doi: 10.1016/j.jchromb.2013.10.032. Epub 2013 Nov 15.

Abstract

This paper describes a full detailed high performance liquid chromatography/tandem mass spectrometry method for the identification and quantification of human urine alpha-aminoadipic semialdehyde, biomarker of pyridoxine-dependent epilepsy. The ionization mode of the electrospray interface was negative and the metabolite was detected in the multiple reaction monitoring mode. Intra-day and inter-day laboratory precision were 4.64% and 7.30%, respectively, total run time was 3.5min. The calibration curve was linear between 0.25 and 10nmol with a correlation coefficient of the calibration line (R(2)≥0.9984); the limit of quantification was 0.25nmol within the control group. This simple, fast, high reproducible and robust procedure facilitates a rapid diagnosis of patients with pyridoxine-dependent epilepsy and can also be used to confirm the elevated urinary alpha-aminoadipic semialdehyde excretion in patients with other metabolic diseases as molybdenum cofactor and isolated sulphite oxidase deficiencies.

Keywords: Alpha-aminoadipic semialdehyde; Antiquitin; Isolated sulphite oxidase deficiency; Molybdenum cofactor deficiency; Pyridoxine-dependent epilepsy.

MeSH terms

  • 2-Aminoadipic Acid / analogs & derivatives*
  • 2-Aminoadipic Acid / urine
  • Adolescent
  • Child, Preschool
  • Chromatography, Liquid / methods*
  • Epilepsy
  • Humans
  • Infant
  • Infant, Newborn
  • Linear Models
  • Metal Metabolism, Inborn Errors / diagnosis*
  • Metal Metabolism, Inborn Errors / urine*
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Tandem Mass Spectrometry / methods*

Substances

  • 2-Aminoadipic Acid
  • allysine

Supplementary concepts

  • Pyridoxine-dependent epilepsy